I will be interested to see how they value potential deal given OPT302 is only part of the medication for wAMD. I guess it will in effect be used with a 'generic' by the time its approved, so the patent protected enhanced treatment should carry close to the full value of the combination treatment. It will also depend on whether any deal locks out competitor products from also being used in a combination therapy with OPT302.
Ann: Opthea's OPT-302 Granted Fast-Track for wet AMD, page-35
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.5¢ |
Change
0.020(2.52%) |
Mkt cap ! $1.003B | |||
| Open | High | Low | Value | Volume |
| 80.0¢ | 83.0¢ | 79.5¢ | $1.320M | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18690 | 81.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 29000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |